Dimethyl Sulfoxide USP, PhEur in Approved Pharmaceutical Products and Medical Devices - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Dimethyl Sulfoxide USP, PhEur in Approved Pharmaceutical Products and Medical Devices
The authors survey the approved applications of dimethyl sulfoxide USP, PhEur across the healthcare industry and consider the suitability of DMSO from a regulatory and formulation compatibility standpoint.


Pharmaceutical Technology


References

1. J.G Harter, "The Status of Dimethyl Sulfoxide from the Perspective of the Food and Drug Administration," Ann. N.Y. Acad. Sci. 411, 11–13 (1983).

2. L.F. Rubin and K.C. Barnett, "Ocular Effects of Oral and Dermal Applications of Dimethyl Sulfoxide in Animals," Ann. N.Y. Acad. Sci. 141, 333–345 (1967).

3. J.M Fischer, "DMSO: A Review," US Pharmacist 25–32 (Sept.1981).

4. A.M.A. Department of Drugs, Agents Used to Treat Interstitial Cystitis in A.M.A Drug Evaluations (American Medical Association, Chicago, IL 4th ed., 1980), pp. 617–618.

5. R.G. Strickley, "Solubilizing Excipients in Oral and Injectable Formulations," Pharm. Res. 21 (2), 225 (2004).

6. FDA Center for Drug Evaluation and Research, Inactive Ingredient Database, http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm (Sept. 14, 2007), accessed Mar. 14, 2008.

7. Onyx Liquid Embolic System: Instructions for Use (Microtherapeutics Corp., Irvine, CA)

8. R.R. Dmochowski, "Tegress Urethral Implant Phase III Clinical Experience and Product Uniqueness," Rev. Urol. 7 (suppl 1), S22–S26 (2005).

9. E.R. Smith, Z. Hadidian, and M.M. Mason, "The Single and Repeated Dose Toxicity of Dimethyl Sulfoxide," Ann. N.Y. Acad. Sci. 141, 96 (1967).

10. C.F. Brayton, "Dimethyl Sulfoxide (DMSO): A Review," Cornell Vet. 76, 60–90 (1986).

11. Code of Federal Regulations, Title 21, Food and Drugs (General Services Administration, Washington, DC, Jan. 19, 2001), Part 1271.10 (a).

12. Organon Tenika, NucliSens HIV-1Q (Nov. 13, 2001), http://www.fda.gov/cber/pmalabel/P0100010LB.pdf, accessed Mar. 14, 2008.

13. A. Aliago et al., "A Topical Solution of 40% Idoxuridine in Dimethyl Sulfoxide Compared to Oral Acyclovir in the Treatment of Herpes Zoster. A Double-Blind Multicenter Clinical Trial," Med Clin 98 (7), 245 (1992).

14. A. Ely and B. Lockwood "What is the Evidence for the Safety and Efficacy of Dimethyl Sulfoxide and Methylsulfonylmethane in Pain Relief?" The Pharmaceutical Journal 269, 685–687 (2001).

15. Gaylord Chemical, Dimethyl Sulfoxide (DMSO) Solubility Data, (Sept. 2, 2007), http://www.gaylordchemical.com/bulletins/Bulletin102B/index.htm, accessed Mar. 14, 2008.

16. R.C. Rowe, P.J. Sheskey, and S.C. Owen, The Handbook of Pharmaceutical Excipients (Pharmaceutical Press, London, UK, 5th ed., 2006)

17. R.Woodford and B.W. Barry "Penetration Enhancers and the Percutaneous Absorption of Drugs: An Update" J. Toxicol. Cut. Ocular Toxicol. 5 (3), 167–177 (1986).

18. G. Kvakovszky and A.S. McKim, Gaylord Chemical Company LLC, previously unpublished data.

19. USP 28–NF 23 (United States Pharmacopeial Convention, Inc., Rockville, MD, 2005), pp. 662–664.

20. European Pharmacopoeia (Council of Europe, Strasbourg, 2002), p. 1055.

21. ICH, Q3C : Impurities: Residual Solvents, http://www.fda.gov/cder/audiences/iact/ICH_Q3C.htm (Oct. 2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here